The case for & against
Bull & Bear analysis
Eli Lilly and Company (NYSE: LLY) is a leading global pharmaceutical company focused on innovative therapies for conditions including diabetes, oncology, and obesity. The company stands out in the incretin therapies segment, particularly with its GLP-1 medications like Mounjaro and Orphoglipron, capitalizing on the growing demand for obesity treatments. As a dominant player in the obesity management space, Eli Lilly is set to leverage its capabilities to expand access to groundbreaking therapies aimed at chronic health issues, positioning itself favorably amidst intensifying competition.
Bull says
- ↑Q1 revenue of $19.8 B, up 20% YoY, led by obesity and diabetes medicines
- ↑EPS rose to $2.05 from $1.50 YoY, reflecting volume expansion in new therapies
- ↑Five Phase III trials underway, with Orphaglipron poised as an obesity blockbuster
- ↑Guidance targets $80–83 B revenue by 2026 via global incretin therapy rollout
- ↑Medicare expansion and Foundeo launch drove 20,000+ patient activations post-launch
- ↑Strong profitability factors, high balance sheet quality, and low price volatility
Bear says
- ↓High forward P/E and negative earnings yield cast valuation concerns
- ↓Price drag in low-to-mid teens could slow future revenue growth
- ↓Short interest remains elevated, signaling investor skepticism on margins
- ↓Execution risk for Foundeo and Orphaglipron may delay adoption
- ↓Medicaid and employer coverage limits could hamper patient access
- ↓Low liquidity and weak dividend yield deter income-focused investors
Investment themes with LLY
Companies with strong fundamentals and stability
Drug development driving global healthcare solutions
Products and services targeting weight management
Services and products for aging population
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- we're excited about the Foundeo launch as it follows an accelerated path in primary care, particularly with early access on the commercial side having two of the three being activated in the next couple of weeks.
- We feel pretty good about all of the actions we're taking, the three key factors, and the pace at which we are activating all three components.
- with results from ACHIEVE-4, cardiovascular safety and a lower risk of all-cause death are added to the clinical profile
Bear points
- around 55% of new patient starts are coming through self-pay for most of which is coming through Lilly Direct or telehealth players, which is a component of reducing some of the frictions in place.
- they couldn't cross with the major players for calendar 27.